These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 6753737)

  • 1. Susceptibility to 5-fluorocytosine and prevalence of serotype in 402 Candida albicans isolates from the United States.
    Stiller RL; Bennett JE; Scholer HJ; Wall M; Polak A; Stevens DA
    Antimicrob Agents Chemother; 1982 Sep; 22(3):482-7. PubMed ID: 6753737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antifungal activity of 5-fluorocytosine as measured by disk diffusion susceptibility testing.
    Utz CJ; Shadomy S
    J Infect Dis; 1977 Jun; 135(6):970-4. PubMed ID: 325150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative in vitro antifungal susceptibility studies with 30 serotype A and B isolates of Candida albicans.
    Shadomy S; Shadomy HJ
    Diagn Microbiol Infect Dis; 1991; 14(1):21-2. PubMed ID: 2013207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of in vitro susceptibility test results with in vivo response: flucytosine therapy in a systemic candidiasis model.
    Stiller RL; Bennett JE; Scholer HJ; Wall M; Polak A; Stevens DA
    J Infect Dis; 1983 Jun; 147(6):1070-7. PubMed ID: 6343524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study of 666 strains of Candida albicans: correlation between serotype and susceptibility to 5-fluorocytosine.
    Auger P; Dumas C; Joly J
    J Infect Dis; 1979 May; 139(5):590-4. PubMed ID: 374653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro susceptibility to 5-fluorocytosine and nystatin of common clinical yeast isolates.
    Nobre G; Sobral T; Ferreira AF
    Mycopathologia; 1981 Jan; 73(1):39-41. PubMed ID: 7012631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Candida albicans resistance to 5-fluorocytosine: frequency of partially resistant strains among clinical isolates.
    Defever KS; Whelan WL; Rogers AL; Beneke ES; Veselenak JM; Soll DR
    Antimicrob Agents Chemother; 1982 Nov; 22(5):810-5. PubMed ID: 6758690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The susceptibility of Candida albicans to amphotericin B, nystatin, and 5-fluorocytosine.
    Hamra LK; Pankiewicz IJ
    Med J Aust; 1977 Nov; 2(22):749-50. PubMed ID: 347230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergism of amphotericin B and 5-fluorocytosine for candida species.
    Montgomerie JZ; Edwards JE; Guze LB
    J Infect Dis; 1975 Jul; 132(1):82-6. PubMed ID: 1097545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Segregation of 5-fluorocytosine-resistance variants by Candida albicans.
    Whelan WL; Beneke ES; Rogers AL; Soll DR
    Antimicrob Agents Chemother; 1981 Jun; 19(6):1078-81. PubMed ID: 7023383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined in vitro activity of amphotericin B and 5-fluorocytosine against Cryptococcus neoformans and Candida albicans.
    Chen HH; Liushih RN; Hsieh WC
    Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1982 May; 15(2):106-12. PubMed ID: 7047097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assay for yeast susceptibility to 5-fluorocytosine and amphotericin B in a frozen microtiter system.
    Ellis NS; Bartlett MS; Smith JW
    Am J Clin Pathol; 1979 Aug; 72(2):194-8. PubMed ID: 382827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complementation analysis of resistance to 5-fluorocytosine in Candida albicans.
    Whelan WL; Markie D; Kwon-Chung KJ
    Antimicrob Agents Chemother; 1986 May; 29(5):726-9. PubMed ID: 3524427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of action of 5-fluorocytosine.
    Waldorf AR; Polak A
    Antimicrob Agents Chemother; 1983 Jan; 23(1):79-85. PubMed ID: 6338821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Assessment of the sensitivity to antifungal agents of clinical isolates of Candida albicans serotype A and B by the ATB Fungus method].
    Quindós G; San Millán R; Burgos A; Lipperheide V; Tellaetxe M; Alonso R; Barturen B; Pontón J
    Enferm Infecc Microbiol Clin; 1995 Apr; 13(4):209-12. PubMed ID: 7779872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro susceptibility of Candida albicans, Austria 1992.
    Allerberger F; Fassl A; Niederwieser D; Zangerle R; Lingnau W; Dierich MP
    Mycoses; 1993; 36(11-12):411-6. PubMed ID: 7935573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Sensitivity and resistance of pathogenic yeasts to 5-fluoropyrimidines. I.--Relation between the phenotypes of resistance to 5-fluorocytosine, the serotype of Candida albicans and the ecology of various species of Candida of human origin (author's transl)].
    Drouhet E; Mercier-Soucy L; Montplaisir S
    Ann Microbiol (Paris); 1975; 126B(1):25-39. PubMed ID: 1108732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro susceptibility testing of Candida isolates from clinical specimens to four antifungal agents.
    Ohkawa M; Tokunaga S; Takashima M; Nishikawa T; Hisazumi H; Fujita S; Wheat RW
    Chemotherapy; 1990; 36(6):396-402. PubMed ID: 2292203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro susceptibilities of sucrose-negative Candida tropicalis, Candida lusitaniae, and Candida norvegensis to amphotericin B, 5-fluorocytosine, miconazole, and ketoconazole.
    Ahearn DG; McGlohn MS
    J Clin Microbiol; 1984 Mar; 19(3):412-6. PubMed ID: 6325491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of a survey of antifungal susceptibility tests in the United States and interlaboratory comparison of broth dilution testing of flucytosine and amphotericin B.
    Calhoun DL; Roberts GD; Galgiani JN; Bennett JE; Feingold DS; Jorgensen J; Kobayashi GS; Shadomy S
    J Clin Microbiol; 1986 Feb; 23(2):298-301. PubMed ID: 3517051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.